Oral Anticoagulants Market is Booming Worldwide with Current Trends, growth, va

Posted by Nita on November 18th, 2019

Oral Anticoagulants Market Research Report - Global Forecast till 2023 : Increasing cardiovascular disorders, rising geriatric population, and increasing surgical procedures would support market growth

In this MRFR market note, the global oral anticoagulants market is discussed at length. Market Research Future (MRFR) forecasts a CAGR of 12.50% for global oral anticoagulants market from 2017 to 2023. The market growth is linked to increased cardiovascular disorders, rising geriatric population, and increasing surgical procedures.

Anticoagulant is a drug, when added to blood, prevents it from clotting. Anticoagulants achieve their effect by suppressing the synthesis or function of various clotting factors that are normally present in the blood. Such drugs are often used to prevent the formation of blood clots (thrombi) in the veins or arteries or the enlargement of a clot that is circulating in the bloodstream.

Currently, the market is dominated by many market players. The growing competition among the existing and new market players to develop better oral anticoagulant is expected to fuel market growth. For instance, in October 2015, Boehringer Ingelheim GmbH announced the US Food and Drug Administration (FDA) approval of Praxbind.

The atrial fibrillation (AF)/stroke prevention segment, will dominate the disease indication segment in the global oral anticoagulants market

The atrial fibrillation (AF)/ stroke prevention segment is accounted for the largest share, holding a market value of USD 6,518.49 in 2017 and is expected to grow at the fastest CAGR of 13.42% during the forecast period 2017 to 2023.

The novel oral anticoagulant segment will dominate the product segment in the global oral anticoagulants market

The novel oral anticoagulant segment is accounted for the largest share, holding a market value of USD 9,054.02 in 2017 and expected to grow at the fastest CAGR of 12.96% during the assessment period from 2017 to 2023.

The hospital pharmacies segment will dominate the distribution channels segment in the global oral anticoagulants market

The Hospital Pharmacies segment is accounted for the largest share, holding a market value of USD 4,944.13 in 2017 and expected to grow at the fastest CAGR of 12.48% during the assessment period from 2017 to 2023.

Asia-Pacific oral anticoagulants market to exhibit the highest CAGR

Asia-Pacific is the fastest growing market for oral anticoagulants and is expected to register a CAGR of 13.10% during the assessment period. Developing regions such as China, India, and South Korea have evolved as a cost-effective manufacturing platform for the oral anticoagulants market.

Vendor Landscape

AstraZeneca, Plc (UK), Pfizer (US), Boehringer Ingelheim GmbH (Germany), Daiichi Sankyo Company Ltd (Japan), Abbott Laboratories (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK) Portola Pharmaceuticals Inc. (US), Medicure (Canada), Johnson & Johnson Services Inc. (US), and others are some of the key companies operating in the oral anticoagulants market.

Global Oral Anticoagulants Market Information: By Product (Novel Oral Anticoagulant and Warfarin), By Disease Indication (Atrial Fibrillation, Deep Vein Thrombosis/ Pulmonary Embolism), By Distribution Channel (Hospital Pharmacies)—Forecast till 2023 : https://www.marketresearchfuture.com/reports/oral-anticoagulants-market-7718